Companies: 10,795·Total market cap: $144.5T
Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics, Inc.

FULCNASDAQHealthcare● Active
$3.69
+$0.32(+9.50%)
Market Cap$199670985
P/E Ratio
52W High$15.74
52W Low$2.83
Overview

Fulcrum Therapeutics, Inc. (FULC) Stock Overview

Key statistics and deep links to earnings, valuation, revenue, dividends, and more.

FMP · FULC · as of Jun 8, 2026

Key Statistics

EPS (TTM)$-1.15fulc eps ttm · fulc earnings per shareEarnings history
PE Ratio (TTM)fulc pe ratio ttm · fulc price to earningsPE Ratio deep dive
Revenue (TTM)0.00fulc revenue ttm · fulc annual revenueFull revenue history
Dividend YieldNo Dividenddoes fulc pay dividends · fulc dividend yieldDividend history
Shares Outstanding63.4Mfulc shares outstanding · fulc floatShares outstanding history
Next EarningsAug 4, 2026Est.fulc earnings date · fulc next earningsEarnings history

Financial Snapshot

Full Financials
FY 2025Revenue$0.00▼ 100.00% YoY
202320242025
fulcrum therapeutics, inc. revenue · fulc revenue 2025
FY 2025Net Income-$74.9M▼ 669.97% YoY
202320242025
fulcrum therapeutics, inc. net income · fulc profit 2025
FY 2025EPS$-1.18▼ 637.50% YoY
202320242025
fulc eps · fulcrum therapeutics, inc. earnings per share 2025
TTM:Revenue: $0.00Net Income: -$76.1MEPS: $-1.15View income statement →

Analyst Ratings & Price Target

Full Forecast
SellBuy
Buy17 analystsis fulc a buy · fulc analyst rating
Strong Buy
0
Buy
7
Hold
7
Sell
3
Strong Sell
0
12-Month Price Target
$3.00Low
$3.69Current
$9.63Avg Target160.98% upside
$25.00High
fulc price target · fulc 12 month forecast

Total: 17 · Buy rate: 41.2%

The FULC analyst consensus is Buy, based on ratings from 17 Wall Street analysts over the past 3 months. The average 12-month price target is $9.63, representing +160.98% upside from the current price of $3.69.

Stock Performance

Full History
1D+9.50%
1W+18.65%
1M-47.36%
3M-54.83%
YTD-67.37%
1Y-48.17%
5Y-59.63%

About Fulcrum Therapeutics, Inc.

CEOAlexander C. Sapir
IPO DateJul 18, 2019
Employees45
CountryUS

Fulcrum Therapeutics, Inc. a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet …

what is fulcrum therapeutics, inc. · fulc stock overview · fulcrum therapeutics, inc. company profile · who is fulcrum therapeutics, inc. ceo · fulc NASDAQ · fulcrum therapeutics, inc. headquarters · fulcrum therapeutics, inc. business segments

About Stock Overview & Key Data

Fulcrum Therapeutics, Inc. (FULC) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Jul 18, 2019. As of the latest trading session, FULC stock price is $3.69, with a market capitalization of $199.7M. The stock has returned -48.17% over the past 12 months and -67.37% year-to-date.

According to 17 Wall Street analysts, the consensus rating for Fulcrum Therapeutics, Inc. stock is Buy, with an average 12-month price target of $9.63. In fiscal year 2025, Fulcrum Therapeutics, Inc. reported revenue of — and net income of -$74.9M. For detailed data — including Fulcrum Therapeutics, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.

Frequently Asked Questions

As of the latest trading session, Fulcrum Therapeutics, Inc. (FULC) stock price is $3.69. The stock is traded on NASDAQ under the ticker symbol FULC. The 52-week range is $2.83 – $15.74.

FULC stock priceFULC quote todaylive ticker
Data provided by Financial Modeling PrepLast updated: Jun 8, 2026Not investment advice